• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Recombinant Human IL-5 protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0380

Validation Data Gallery

Product Information

Purity >90 %, SDS-PAGE
Endotoxin <1.0 EU/μg protein, LAL method
Activity 
Not tested
Expression HEK293-derived Human IL-5 protein Met1-Thr103 (Accession# P05113) with a His tag at the C-terminus.
GeneID 3567
Accession P05113
PredictedSize 17.5 kDa
SDS-PAGE
Formulation Lyophilized from sterile PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

IL-5 (interleukin-5) is a key cytokine, secreted mainly by Th2 cells and mast cells, that plays an important role in the development, differentiation and activation of eosinophils. IL-5 promotes eosinophil maturation, survival and degranulation through signaling mediated by its receptor (IL-5R), thus playing a role in allergic reactions and inflammatory processes. In allergic diseases (e.g., asthma), elevated levels of IL-5 are associated with a large increase in eosinophils, making IL-5 a potential target for the treatment of these diseases. For example, anti-IL-5 monoclonal antibodies (e.g., mepolizumab and rilizumab) have been approved for the treatment of severe eosinophilic asthma. In addition, IL-5 plays a role in other eosinophil-associated diseases (e.g., nasal polyps) and may be involved in the regulation of the tumor microenvironment.

References:

1. Jackson, David J et al. Allergy vol. 79,11 (2024): 2943-2952.                                                                                                        2. Dougan, Michael et al. Immunity vol. 50,4 (2019): 796-811.                                                                                                      3. Blomberg, Olga S et al. Cancer cell vol. 41,1 (2023): 106-123.e10.                                                                                                 4. Gevaert, Philippe et al. International forum of allergy & rhinology vol. 12,11 (2022): 1413-1423.